Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers

被引:1
|
作者
Lin, Hui [1 ,2 ]
Tian, Yuan [1 ,2 ]
Tian, Ji-Xin [1 ,2 ]
Zhang, Zun-Jian [1 ,2 ]
Mao, Guo-Guang [3 ]
机构
[1] China Pharmaceut Univ, Ctr Instrumental Anal, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Minist Educ, Key Lab Drug Qual Control & Pharmacovigilance, Nanjing 210009, Peoples R China
[3] Wannan Med Coll, Dept Clin Pharmacol, Wuhu, Peoples R China
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2010年 / 60卷 / 03期
关键词
Acyclovir; Antiviral drugs; CAS; 59277-89-3; 124832-26-4; 214832-27-5; Valacyclovir; Valacyclovir hydrochloride; bioequivalence; pharmacokinetics; L-VALYL ESTER; ANTIVIRAL ACTIVITY; THERAPEUTIC-EFFICACY; ORAL VALACYCLOVIR; ACYCLOVIR; VALACICLOVIR; DISEASE; DRUG;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of the present study was to compare the bioavailability of valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule as test preparation and 150 mg/capsule commerciallty available original capsule of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 20 and 27. The study was conducted according to an open randomized, single blind, 2-way crossover study design with a wash-out phase of 7 days. Blood samples for pharmacokinetic profiling were taken up to 24 h post-dose. Valacyclovir hydrochloride is rapidly converted to acyclovir (CAS 59277-89-3) after oral administration, so the pharmacokinetcis and bioequivalence of valacyclovir hydrochloride can be studied by determining the plasma concnetratio of acyclovir. Plasma concentrations of acyclovir were determined witha validated liquid chromatography, tandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C-max) were 2.04 +/- 0.43 mu g mL and 2.01 +/- 0.50 mu g/mL; the median T-max were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t(1/2)) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h Values of AUC(0-t) demonstrate nearly identical bioavailability of valacyclovir hydrochloride from the examined formulations. AUC(0-15) were 6.70 +/- 1.26 mu g.h/mL and 6.96 +/- 1.25 g.h/mL. Areas under the plasma concentration-time curve (AUC(0-infinity)) were 6.90 +/- 1.36 mu g.h/ml and 7.15 +/- 1.31 mu g.h/mL. Both primary target parameters , AUC(0-infinity) and AUC(0-t) wre tested parametrically by analysis of variaance (ANOVA) and relative bioavailabilities were 96.69 7.89% for AUC(0-infinity) , 96.40 8.0% for AUC(0-15). Bioequivalence between test and reference preparation was demonstated fro both parameters AUC(0-infinity) and AUC(0-t). The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80-125%. It meant that the test formualtion was bioequivalnet to the reference formulation for valacyclovir hydrochloride.
引用
收藏
页码:162 / 167
页数:6
相关论文
共 50 条
  • [31] Study on the pharmacokinetics and bioequivalence of etodolac in Chinese healthy volunteers
    Jiang, Min
    Zhang, Hong
    Xiong, Yu-qing
    Chinese Pharmaceutical Journal, 2002, 37 (08) : 608 - 611
  • [32] Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers
    Wittayalertpanya, Supeecha
    Chariyavilaskul, Pajaree
    Prompila, Nantaporn
    Sayankuldilok, Nonlanee
    Eiamart, Wanna
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (05) : 431 - 436
  • [33] Single-dose pharmacokinetics and safety of iptakalim hydrochloride in Chinese healthy volunteers
    Cai, Yun
    Chai, Dong
    Pei, Fei
    Fang, Yi
    Wang, Rui
    Liang, Bei-bei
    Cui, Wen-yu
    Bao, Cun-gang
    Wang, Hai
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (03) : 337 - 343
  • [34] Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers
    Lue Yuan
    Kang Zi-sheng
    Zhu Yan
    Zhang Ming
    Liu Yan
    Zhang Man
    Li Tian-yun
    Xiao Yong-hong
    CHINESE MEDICAL JOURNAL, 2011, 124 (02) : 242 - 245
  • [35] BIOEQUIVALENCE STUDY OF DULOXETINE HYDROCHLORIDE 60 MG EC CAPSULES IN THE FASTING AND FED STATES IN HEALTHY THAI MALE VOLUNTEERS
    Techatanawat, Isariya
    Bhuket, Pahweenvaj Ratnatilaka Na
    Teerawonganan, Polsak
    Yoosakul, Ekawan
    Khaowroongrueng, Vipada
    Paisarnsinsook, Wiriya
    Chuasuwan, Bancha
    Narakorn, Piengthong
    Rojanawiwat, Archawin
    Eksaengsri, Achara
    JOURNAL OF HEALTH RESEARCH, 2015, 29 (03) : 165 - 169
  • [36] Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
    Wang, Ying
    Wang, Tongtong
    Fang, Han
    Huang, Hui
    Fang, Lijuan
    Zhang, XuanGuo
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (06): : 687 - 694
  • [37] Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5-mg Capsules After Single-Dose Administration in Healthy Subjects
    VanderLugt, James T.
    Bon, Charles
    Knuth, Dean
    Schreiber, Rhonda
    Ruff, Michael D.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (03): : 311 - 318
  • [38] Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings
    Wang, Tongtong
    Wang, Yannan
    Lin, Sisi
    Fang, Lu
    Lou, Sai
    Zhao, Di
    Zhu, Jingjing
    Yang, Qigang
    Wang, Ying
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (06)
  • [39] Investigation of the bioequivalence of two lansoprazole formulations in healthy Chinese volunteers after a single oral administration
    Bian, Yuhai
    Zhong, Ming
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2017, 45 (07) : 1425 - 1430
  • [40] Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study
    Lu, Kang
    Lin, Sisi
    Wang, Yannan
    Hao, Rui
    Fang, Lu
    Zhu, Jingjing
    Zhao, Di
    Yu, Jin
    Tong, Shengjia
    Wu, Yi
    Si, Yongkai
    Ye, Tiantian
    Yang, Qigang
    Wang, Ying
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 748 - 755